# Avalyn Pharma funding rounds and investors

As of 14 Oct 2026, Avalyn Pharma has raised $100M across 1 verified round on record; latest: $100 million Series D led by SR One and Suvretta Capital Management, announced 23 Jul 2025.

Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners.

Website: https://avalynpharma.com  
Page: https://fireround.dev/companies/avalynpharma.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-07-23 | Series D | $100 million | SR One, Suvretta Capital Management | Catalio Capital Management, Eventide Asset Management, F-Prime Capital, Hamilton Square Partners Management, LP (HSq), Norwest, Novo Holdings, Perceptive Xontogeny Venture Funds (PXV Funds), Piper Heartland, Pivotal bioVenture Partners, RiverVest Venture Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), TPG Biotech, T. Rowe Price, Vida Ventures, Wellington Management | [goodwinlaw.com](https://www.goodwinlaw.com/en/news-and-events/news/2025/07/announcements-lifesciences-goodwin-represents-avalyn-in-oversubscribed) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.